China's leading vaccine producer Sinopharm announced Wednesday that it has submitted an application to Chinese authorities for marketization of its COVID-19 vaccine.
周三，中国领先的疫苗生产商国药集团宣布，已向中国当局提交了新冠疫苗上市申请。
A vice-general manager named Shi Shengyi made the announcement.
国药集团副总经理石晟怡宣布了这一消息。
A representative of Sinopharm told the global Times on Wednesday that Sinopharm had collected data from major countries carrying out its vaccine clinical trials such as UAE. Results are expected to be good but it is up to Chinese authorities to make the decision as the authorities have strict review standards.
国药集团的一位代表于周三对《环球时报》说，国药集团已从进行疫苗临床试验的主要国家(如阿联酋)收集了数据。预期结果会很好，但因为国家当局具有严格的审查标准，最后决定将由中国当局做出。
Sinopharm previously told the Global Times that it had reported the phase-III clinical data to China's state Food and Drug Administration and was in the process of giving more detailed data, as requested.
国药集团此前告诉《环球时报》，已向中国国家食品药品监督管理局报告了三期临床数据，正在按照要求提供更详细的数据。
The vaccine maker says it is in the final stage before marketization, and is now making approval for the marketization of the vaccine its top priority. It will be possible to release the phase three data in academic journals after the approval.
这家疫苗生产商说，他们正处于上市之前的最后阶段，目前正将批准疫苗市场化作为其首要任务。批准后，将有可能在学术期刊中发布第三阶段的数据。
“Our data is evaluated by relevant departments following protocols even stricter than in some Western countries, and we are in close communication with the WHO," a representative of Sinopharm told the Global Times previously.
国药的一位代表此前对《环球时报》说，“我们的数据是由相关部门按照甚至比某些西方国家更为严格的协议评估的，我们与世界卫生组织保持着密切联系。”
英文来源：Global Times
湘公网安备43011202000971号